Olanzapine/risperidone

Olanzapine/risperidone Reactions 1680, p267 - 2 Dec 2017 Extrapyramidal side effects: case report A 48-year-old man developed extrapyramidal side effects during treatment with olanzapine and risperidone. The man had a history of bilateral otitis media and had undergone bilateral myringoplasty at the age of 18 years. At the age of 38 years, he presented with psychiatric symptoms, for which he received risperidone. Following 9.5 years of this treatment, his symptoms worsened for several times due to the discontinuation of treatment. However, after commencing individual treatment with olanzapine 20mg and risperidone 8mg for three weeks each [route not stated], the symptoms persisted. He developed extrapyramidal side effects [duration of treatment to reaction onset and outcome not stated]. The man’s antipsychotic therapy was switched to trifluoperazine and he received trihexyphenidyl to manage extrapyramidal side effects. Author comment: ’’Despite individual treatment with risperidone 8 mg and olanzapine 20 mg for 3weeks each, the symptoms did not improve. However, within 2 weeks of switching to trifluoperazine 30 mg and trihexyphenidyl 4–6 mg (to manage extrapyramidal side effects), his psychotic symptoms improved completely’’. Jain S, et al. Improvement of tinnitus with trifluoperazine in a patient with psychosis and ear disease. Asian Journal of Psychiatry 30: 177-178, Dec 2017. Available from: URL: http://doi.org/10.1016/j.ajp.2017.10.027 - India 803284172 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Olanzapine/risperidone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/olanzapine-risperidone-uyCAYngB4B
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39198-0
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial